Jun 10, 2021 / NTS GMT
Jeff Stent - Exane BNP Paribas - Analyst
Over to you, Brian.
Brian McNamara - GSK Consumer Healthcare - CEO
Yes. Thanks so much, Jeff, for that introduction. I appreciate that. So listen, I'll leave it to all of you at your own time to read the customary disclaimer. So it's great to be here today to talk to you about GSK Consumer Healthcare, the world leader in consumer healthcare, competing in GBP130 billion market that's been growing at about 3.5% a year.
And to talk to you about our exciting journey to separation and listing, which is scheduled to happen in mid-2022. We have a great opportunity ahead of us. At the time of listing, we'll be the first and only listed company 100% focused on consumer health. And with that, we bring a unique combination of a scientific heritage and capability that comes from being part of a pharma company with strong FMCG skills that we've built over time.
Now, this really comes to life in our oral health business, where you see Sensodyne, which is our largest brand, has been able to grow double digits over the
HALEON PLC at Exane BNP Paribas European CEO Conference Transcript
Jun 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers